Invesco Biotechnology & Genome ETF (PBE)
| Assets | $257.47M |
| Expense Ratio | 0.58% |
| PE Ratio | 18.10 |
| Shares Out | 3.77M |
| Dividend (ttm) | $0.03 |
| Dividend Yield | 0.05% |
| Ex-Dividend Date | Jun 24, 2024 |
| Payout Ratio | 0.85% |
| 1-Year Return | +28.80% |
| Volume | 4,746 |
| Open | 68.78 |
| Previous Close | 69.46 |
| Day's Range | 68.20 - 68.78 |
| 52-Week Low | 53.16 |
| 52-Week High | 72.72 |
| Beta | 0.80 |
| Holdings | 33 |
| Inception Date | Jun 23, 2005 |
About PBE
Fund Home PageThe Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering. PBE was launched on Jun 23, 2005 and is issued by Invesco.
Top 10 Holdings
45.23% of assets| Name | Symbol | Weight |
|---|---|---|
| Illumina, Inc. | ILMN | 5.80% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 5.28% |
| United Therapeutics Corporation | UTHR | 5.25% |
| Amgen Inc. | AMGN | 5.02% |
| Biogen Inc. | BIIB | 4.69% |
| BioMarin Pharmaceutical Inc. | BMRN | 4.02% |
| Regeneron Pharmaceuticals, Inc. | REGN | 4.01% |
| Neurocrine Biosciences, Inc. | NBIX | 3.96% |
| MannKind Corporation | MNKD | 3.62% |
| Xencor, Inc. | XNCR | 3.57% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 24, 2024 | $0.0082 | Jun 28, 2024 |
| Mar 18, 2024 | $0.02419 | Mar 22, 2024 |
| Jun 20, 2023 | $0.01407 | Jun 23, 2023 |
| Mar 23, 2020 | $0.02898 | Mar 31, 2020 |
| Sep 24, 2018 | $0.00207 | Sep 28, 2018 |
| Jun 16, 2017 | $0.21532 | Jun 30, 2017 |
News
PBE: Biotech Could Be Next Big Winner
Biotechnology and genomics sector has not performed well in recent years, making it an attractive investment opportunity. The Invesco Biotechnology & Genome ETF offers comprehensive exposure to the bi...
PBE: Healthcare Dashboard For June
Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF.
PBE: Healthcare Dashboard For March
The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality.
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...
What The Inflation Reduction Act Means For Drug Prices
The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs ...
PBE: Neither Lucrative, Nor Competitive
PBE is neither suitable for income seekers, nor for long term investors.
Equity Market Cap For Technologically Enabled Innovation Likely To Grow Exponentially
Investment strategies geared to the future evaluate complex dynamics that can evolve rapidly. As innovation's market share has grown, investment capacity - as measured by average days to trade - also ...
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...
2 Biotech Funds Poised for a Healthy Breakout
Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.
3 Health Care ETFs Where Components Are Enduring Downgrades
After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.
6 Best Biotech ETFs to Buy for Cutting-Edge Growth
Biotech ETFs are, in a word, hot.
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
Investors flee Biotech ETFs as they Lag Bull Market
Many biotech ETFs and other funds have fallen sharply off their highs in recent months.
3 Charts That Suggest Now Is the Time to Buy Into Biotech
Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.